Biomedical papers, 2013 (vol. 157), issue 2

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013, 157(2):146-152 | 10.5507/bp.2013.033

Common biomarkers of oxidative stress do not reflect cardiovascular dys/function in rats

Premysl Mladenkaa, Libuse Zatloukalovaa, Tomas Filipskya, Jaroslava Vavrovab, Magdalena Holeckovab, Vladimir Palickab, Radomir Hrdinaa
a Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic
b Institute for Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove, Hradec Kralove

Background: Predicting cardiovascular events remains challenging despite the range of known biomarkers.

Aim: To establish relationships between various biochemical and functional parameters of the cardiovascular system.

Method: The relationship between cardiovascular dys/function and various biomarkers was examined in 145 experimental rats half of which received isoprenaline 100 mg/kg s.c. to induce cardiac impairment.

Results: Serum concentration of cardiac troponin T (cTnT), a known marker of cardiac derangement, correlated strongly with degree of myocardial injury (e.g. calcium overload, stroke volume) but correlations between cTnT and oxidative stress parameters were weak (for glutathione and vitamin C) or not found (for serum vitamin E and plasma thiobarbituric acid reactive substances levels). Relationships between cTnT and other parameters were exponential with the exception of myocardial calcium, where a power function was found.

Conclusions: Commonly used biomarkers of oxidative stress cannot reliably predict cardiovascular dys/function in experimental rats.

Keywords: oxidative stress, cardiovascular disease, catecholamines, acute myocardial infarction

Received: November 1, 2012; Accepted: April 25, 2013; Prepublished online: May 28, 2013; Published: June 21, 2013


References

  1. Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010;105(1 Suppl):3A-9A. Go to original source... Go to PubMed...
  2. Goldberg RJ, Glatfelter K, Burbank-Schmidt E, Lessard D, Gore JM. Trends in community mortality due to coronary heart disease. Am Heart J 2006;151(2):501-7. Go to original source... Go to PubMed...
  3. Wilkins JT, Lloyd-Jones DM. Biomarkers for coronary heart disease clinical risk prediction: a critical appraisal. Counterpoint. Prev Cardiol 2010;13(4):160-5. Go to original source... Go to PubMed...
  4. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;370(9603):1929-38. Go to original source... Go to PubMed...
  5. Fearon IM, Faux SP. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 2009;47(3):372-81. Go to original source... Go to PubMed...
  6. Strobel NA, Fassett RG, Marsh SA, Coombes JS. Oxidative stress biomarkers as predictors of cardiovascular disease. Int J Cardiol 2011;147(2):191-201. Go to original source... Go to PubMed...
  7. Peng YX, Shan J, Qi XY, Zhang SJ, Ma SP, Wang N, Li JP, Xue H, Wu M. The catecholamine-beta-adrenoreceptor-cAMP system and prediction of cardiovascular events in hypertension. Clin Exp Pharmacol Physiol 2006;33(3):227-31. Go to original source... Go to PubMed...
  8. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985;17(4):291-306. Go to original source... Go to PubMed...
  9. Krenek P, Kmecova J, Kucerova D, Bajuszova Z, Musil P, Gazova A, Ochodnicky P, Klimas J, Kyselovic J. Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. Eur J Heart Fail 2009;11(2):140-6. Go to original source... Go to PubMed...
  10. Mladenka P, Hrdina R, Bobrovova Z, Semecky V, Vavrova J, Holeckova M, Palicka V, Mazurova Y, Nachtigal P. Cardiac biomarkers in a model of acute catecholamine cardiotoxicity. Hum Exp Toxicol 2009;28(10):631-40. Go to original source... Go to PubMed...
  11. Mladenka P, Kalinowski DS, Haskova P, Bobrovova Z, Hrdina R, Simunek T, Nachtigal P, Semecky V, Vavrova J, Holeckova M, Palicka V, Mazurova Y, Jansson PJ, Richardson DR. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chem Res Toxicol 2009;22(1):208-17. Go to original source... Go to PubMed...
  12. Mladenka P, Semecky V, Bobrovova Z, Nachtigal P, Vavrova J, Holeckova M, Palicka V, Mazurova Y, Hrdina R. The effects of lactoferrin in a rat model of catecholamine cardiotoxicity. Biometals 2009;22(2):353-61. Go to original source... Go to PubMed...
  13. Mladenka P, Zatloukalova L, Simunek T, Bobrovova Z, Semecky V, Nachtigal P, Haskova P, Mackova E, Vavrova J, Holeckova M, Palicka V, Hrdina R. Direct administration of rutin does not protect against catecholamine cardiotoxicity. Toxicology 2009;255(1-2):25-32. Go to original source... Go to PubMed...
  14. Zatloukalova L, Filipsky T, Mladenka P, Semecky V, Macakova K, Holeckova M, Vavrova J, Palicka V, Hrdina R. Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity. Can J Physiol Pharmacol 2012;90(4):473-84. Go to original source... Go to PubMed...
  15. Adamcova M, Simunek T, Kaiserova H, Popelova O, Sterba M, Potacova A, Vavrova J, Malakova J, Gersl V. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 2007;237(1-3):218-28. Go to original source... Go to PubMed...
  16. Gibbons RJ, Valeti US, Araoz PA, Jaffe AS. The quantification of infarct size. J Am Coll Cardiol 2004;44(8):1533-42. Go to original source... Go to PubMed...
  17. Fleckenstein-Grun G, Frey M, Thimm F, Hofgartner W, Fleckenstein A. Calcium overload--an important cellular mechanism in hypertension and arteriosclerosis. Drugs 1992;44 Suppl 1:23-30. Go to original source... Go to PubMed...
  18. Janke J, Fleckenstein A, Doring HJ, Leder O. [Key-role of intracellular calcium overload in acute necrosis of the myocardium. Cardioprotection with verapamil]. Minerva Med 1975;66(38):1846-58. Go to PubMed...
  19. Feldman D, Elton TS, Menachemi DM, Wexler RK. Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine. Vasc Health Risk Manag 2010;6:387-97. Go to original source... Go to PubMed...
  20. Lawes CM, Bennett DA, Lewington S, Rodgers A. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med 2002;2(4):355-68. Go to original source... Go to PubMed...
  21. Jain VK, Mohan G. Serum zinc and copper in myocardial infarction with particular reference to prognosis. Biol Trace Elem Res 1991;31(3):317-22. Go to original source... Go to PubMed...
  22. Arnaud J, Faure H, Bourlard P, Denis B, Favier AE. Longitudinal changes in serum zinc concentration and distribution after acute myocardial infarction. Clin Chim Acta 1994;230(2):147-56. Go to original source... Go to PubMed...
  23. Bor MV, Cevik C, Uslu I, Guneral F, Duzgun E. Selenium levels and glutathione peroxidase activities in patients with acute myocardial infarction. Acta Cardiol 1999;54(5):271-6. Go to PubMed...
  24. Kok FJ, Hofman A, Witteman JC, de Bruijn AM, Kruyssen DH, de Bruin M, Valkenburg HA. Decreased selenium levels in acute myocardial infarction. Jama 1989;261(8):1161-4. Go to original source... Go to PubMed...
  25. Zachara BA, Ukleja-Adamowicz M, Nartowicz E, Lecka J. Increased plasma glutathione peroxidase activity in patients with acute myocardial infarction. Med Sci Monit 2001;7(3):415-20. Go to PubMed...
  26. van der Schouw YT, van der Veeken PM, Kok FJ, Koster JF, Schouten EG, Hofman A. Iron status in the acute phase and six weeks after myocardial infarction. Free Radic Biol Med 1990;8(1):47-53. Go to original source... Go to PubMed...
  27. Cottin Y, Doise JM, Maupoil V, Tanniere-Zeller M, Dalloz F, Maynadie M, Walker MK, Louis P, Carli PM, Wolf JE, Rochette L. Plasma iron status and lipid peroxidation following thrombolytic therapy for acute myocardial infarction. Fundam Clin Pharmacol 1998;12(2):236-41. Go to original source... Go to PubMed...
  28. Dubois-Rande JL, Artigou JY, Darmon JY, Habbal R, Manuel C, Tayarani I, Castaigne A, Grosgogeat Y. Oxidative stress in patients with unstable angina. European Heart Journal 1994;15(2):179-83. Go to original source... Go to PubMed...
  29. Ohlin H, Gustavsson CG, Pantev E, Thorvinger B, Ohlin AK. Transient release of lipid peroxidation products as a non-invasive marker of successful reperfusion after thrombolysis for myocardial infarction. Br Heart J 1995;73(3):223-6. Go to original source... Go to PubMed...
  30. Olsson KA, Harnek J, Ohlin AK, Pavlidis N, Thorvinger B, Ohlin H. No increase of plasma malondialdehyde after primary coronary angioplasty for acute myocardial infarction. Scand Cardiovasc J 2002;36(4):237-40. Go to original source... Go to PubMed...
  31. Dwivedi VK, Chandra M, Misra PC, Misra A, Misra MK. Status of some free radical scavenging enzymes in the blood of myocardial infarction patients. J Enzyme Inhib Med Chem 2006;21(1):43-6. Go to original source... Go to PubMed...
  32. Pucheu S, Coudray C, Vanzetto G, Favier A, Machecourt J, de Leiris J. Assessment of radical activity during the acute phase of myocardial infarction following fibrinolysis: utility of assaying plasma malondialdehyde. Free Radic Biol Med 1995;19(6):873-81. Go to original source... Go to PubMed...
  33. Lafont A, Marwick TH, Chisolm GM, Van Lente F, Vaska KJ, Whitlow PL. Decreased free radical scavengers with reperfusion after coronary angioplasty in patients with acute myocardial infarction. Am Heart J 1996;131(2):219-23. Go to original source... Go to PubMed...
  34. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005;10 Suppl 1:S10-23. Go to original source... Go to PubMed...
  35. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med 2007;43(1):4-15. Go to original source... Go to PubMed...
  36. Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 1992;13(4):391-405. Go to original source... Go to PubMed...
  37. Haskova P, Kovarikova P, Koubkova L, Vavrova A, Mackova E, Simunek T. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. Free Radic Biol Med 2011;50(4):537-49. Go to original source... Go to PubMed...
  38. Chagoya de Sanchez V, Hernandez-Munoz R, Lopez-Barrera F, Yanez L, Vidrio S, Suarez J, Cota-Garza MD, Aranda-Fraustro A, Cruz D. Sequential changes of energy metabolism and mitochondrial function in myocardial infarction induced by isoproterenol in rats: a long-term and integrative study. Can J Physiol Pharmacol 1997;75(12):1300-11. Go to original source... Go to PubMed...